Targeting VEGF-A to treat cancer and age-related macular degeneration

Annual Review of Medicine

Volumn 58, Issue , 2007, Pages 491-504

  Ferrara, Napoleone ^a   Mass, Robert D ^a   Campa, Claudio ^a   Kim, Robert ^a  

^a GENENTECH INC   (United States)

Author keywords

Angiogenesis; Endothelium; Tumor growth; Tyrosine kinases; Vascular endothelial growth factor

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; BEVACIZUMAB; BORTEZOMIB; FLUOROURACIL; FOLINIC ACID; IMATINIB; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PEGAPTANIB; RANIBIZUMAB; RITUXIMAB; RUBOXISTAURIN; TEMSIROLIMUS; TRASTUZUMAB; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN;

ANGIOGENESIS; BIOLOGY; BLEEDING; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; ENDOPHTHALMITIS; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEINURIA; RETINA MACULA DEGENERATION; REVIEW; STROKE; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS; UVEITIS; DRUG ANTAGONISM; NEOPLASM; PHYSIOLOGY;

ANGIOGENESIS INHIBITORS; HUMANS; MACULAR DEGENERATION; NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34047175559     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.58.061705.145635     Document Type: Review

References (100)

1. Folkman J, Klagsbrun M. 1987. Angiogenic factors. Science 235:442-47
2. Yancopoulos GD, Davis S, Gale NW, et al. 2000. Vascular-specific growth factors and blood vessel formation. Nature 407:242-48
3. Sund M, Hamano Y, Sugimoto H, et al. 2005. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc. Natl. Acad. Sci. USA 102:2934-39
4. Ferrara N. 2002. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2:795-803
5. Ferrara N, Gerber HP, LeCouter J. 2003. The biology of VEGF and its receptors. Nat. Med. 9:669-76
6. Alitalo K, Tammela T, Petrova TV. 2 005. Lymphangiogenesis in development and human disease. Nature 438:946-53
7. Ferrara N, Kerbel RS. 2005. Angiogenesis as a therapeutic target. Nature 438:967-74
8. Leung DW, Cachianes G, Kuang WJ, et al. 1989. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-9
9. Ferrara N. 2004. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25:581-611
10. Dvorak HF. 2002. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20:4368-80
11. Ferrara N, Carver Moore K, Chen H, et al. 1996. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-42
12. Gerber HP, Hillan KJ, Ryan AM, et al. 1999. VEGF is required for growth and survival in neonatal mice. Development 126:1149-59
13. Malik AK, Baldwin ME, Peale F, et al. 2006. Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice. Blood 107:550-57
14. Gerber HP, Vu TH, Ryan AM, et al. 1999. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med. 5:623-28
15. Ferrara N, Chen H, Davis-Smyth T, et al. 1998. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat. Med. 4:336-40
16. Alon T, Hemo I, Itin A et al. 1995. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1:1024-28
17. Gerber HP, Dixit V, Ferrara N. 1998. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J. Biol. Chem. 273:13313-16
18. Gerber HP, McMurtrey A, Kowalski J, et al. 1998. VEGF regulates endothelial cell survival by the PB-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273:30336-43
19. Benjamin LE, Golijanin D, Itin A, et al. 1999. Selective ablation ofimmature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103:159-65
20. Tran J, Master Z, Yu JL, et al. 2002. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl. Acad. Sci. USA 99:4349-54
21. Carmeliet P. 2005. Angiogenesis in life, disease and medicine. Nature 438:932-36
22. Clauss M, Gerlach M, Gerlach H, et al. 1990. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J. Exp. Med. 172:1535-45
23. Barleon B, Sozzani S, Zhou D, et al. 1996. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87:3336-43
24. Gerber H-P, Malik A, Solar GP, et al. 2002. Vascular endothelial growth factor regulates hematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417:954-58
25. Houck KA, Ferrara N, Winer J, et al. 1991. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 5:1806-14
26. Tischer E, Mitchell R, Hartman T, et al. 1991. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266:11947-54
27. Ferrara N, Henzel WJ. 1989. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161:851-58
28. Plouet J, Schilling J, Gospodarowicz D. 1989. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT20 cells. EMBO J. 8:3801-8
29. Houck KA, Leung DW, Rowland AM, et al. 1992. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267:26031-37
30. Park JE, Keller G-A, Ferrara N. 1993. The vascular endothelial growth factor isoforms (VEGF): differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell 4:1317-26
31. Keyt BA, Berleau LT, Nguyen HV, et al. 1996. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J. Biol. Chem. 271:7788-95
32. Lee S, Jilani SM, Nikolova GV, et al. 2005. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J. Cell Biol. 169:681-91
33. Shibuya M, Yamaguchi S, Yamane A, et al. 1990. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family. Oncogene 8:519-27
34. Terman BI, Dougher-Vermazen M, Carrion ME, et al. 1992. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 187:1579-86
35. de Vries C, Escobedo JA, Ueno H, et al. 1992. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255:989-91
36. Park JE, Chen HH, Winer J, et al. 1994. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-/KDR. J. Biol. Chem. 269:25646-54
37. Olofsson B, Korpelainen E, Pepper MS, et al. 1998. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc. Natl. Acad. Sci. USA 95:11709-14
38. LeCouter J, Moritz DR, Li B, et al. 2003. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 299:890-93
39. Hiratsuka S, Nakamura K, Iwai S, et al. 2002. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2:289-300
40. Hattori K, Heissig B, Wu Y, et al. 2002. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR 1(+) stem cells from bone-marrow microenvironment. Nat. Med. 8:841-49
41. Quinn TP, Peters KG, De Vries C, et al. 1993. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc. Natl. Acad. Sci. USA 90:7533-37
42. Shalaby F, Rossant J, Yamaguchi TP, et al. 1995. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376:62-66
43. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. 2006. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 7:359-71
44. Soker S, Takashima S, Miao HQ, et al. 1998. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92:735-45
45. Okada F, Rak JW, Croix BS, et al. 1998. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc. Natl. Acad. Sci. USA 95:3609-14
46. Lonser RR, Glenn GM, Walther M, et al. 2003. Von Hippel-Lindau disease. Lancet 361:2059-67
47. Zhang X, Gaspard JP, Chung DC. 2001. Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res. 61:6050-54
48. Seno H, Oshima M, Ishikawa TO, et al. 2002. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res. 62:506-11
49. Kim KJ, Li B, Winer J, et al. 1993. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362:841-44
50. Manley PW, Martiny-Baron G, Schlaeppi JM, Wood JM. 2002. Therapies directed at vascular endothelial growth factor. Expert Opin. Investig. Drugs 11:1715-36
51. Prewett M, Huber J, Li Y, et al. 1999. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59:5209-18
52. Gerber HP, Kowalski J, Sherman D, et al. 2000. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. 60:6253-58
53. Holash J, Davis S, Papadopoulos N, et al. 2002. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA 99:11393-98
54. Dong J, Grunstein J, Tejada M, et al. 2004. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J. 23:2800-10
55. Tejada M, Yu L, Dong J, et al. 2006. Tumor-driven paracrine PDGF receptor - a signaling is a key determinent of stromal cell recruitment in a model of human lung carcinoma. Clin. Cancer Res. 12:2676-88
56. Klement G, Baruchel S, Rak J, et al. 2000. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105:R15-24
57. Lee CG, Heijn M, di Tomaso E, et al. 2000. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60:5565-70
58. Jain RK. 2005. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62
59. Presta LG, Chen H, O'Connor SJ, et al. 1997. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57:4593-99
60. Ferrara N, Hillan KJ, Gerber HP, Novotny W. 2004. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3:391-400
61. Gasparini G, Longo R, Toi M, Ferrara N. 2005. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat. Clin. Pract. Oncol. 2:562-77
62. Jain RK, Duda DG, Clark JW, Loeffler JS. 2006. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3:24-40
63. Hurwitz H, Fehrenbacher L, Novotny W, et al. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350:2335-42
64. Skillings JR, Johnson DH, Miller K, et al. 2005. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. ASCO Annu. Meet. Proc. Abstr. 3019
65. Sandler AB, Gray R, Brahmer J, et al. 2005. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial - E4599. ASCO Annu. Meet. Proc. Plen. Sess. I Abstr. 4
66. Giantonio BJ, Catalano PJ, Meropol NJ, et al. 2005. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. ASCO Gastro-intest. Cancer Proc. Abstr. 169a
67. Johnson DH, Fehrenbacher L, Novotny WF, et al. 2004. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22:2184-91
68. Yang JC, Haworth L, Sherry RM, et al. 2003. A randomized trial of bevacizumab, an anti-VEGF antibody, for metastatic renal cancer. N. Engl. J. Med. 349:427-34
69. Burger RA, Sill M, Monk BJ, et al. 2005. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study. ASCO Annu. Meet. Proc. Abstr. 5009
70. Picus J, Halabi S, Rini B, et al. 2003. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. ASCO Annu. Meet. Proc. Abstr. 1578
71. Smith JK, Mamoon NM, Duhe RJ. 2004. Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. Oncol. Res. 14:175-225
72. Maki RG, Fletcher JA, Heinrich MC, et al. 2005. Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). ASCO Annu. Meet. Proc. Abstr. 9011
73. Rini B, Rixe O, Bukowski R, et al. 2005. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). ASCO Annu. Meet. Proc. Abstr. 4509
74. Motzer RJ, Dror Michaelson M, Redman BG, et al. 2006. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24:16-24
75. Escudier B, Szczylik C, Eisen T, et al. 2005. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). ASCO Annu. Meet. Proc. Abstr. 4510
76. Wood JM, Bold G, Buchdunger E, et al. 2000. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 60:2178-89
77. Hecht JR, Trarbach T, Jaeger E, et al. 2005. A randomized, double blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxalipla tin/5-fluorouracil/leucovorin and PTK787/ZK222584 or placebo (CONFIRM-1). ASCO Annu. Meet. Proc. Plen. Sess. I Abstr. 3
78. Miller JW, Adamis AP, Shima DT, et al. 1994. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am. J. Pathol. 145:574-84
79. Safran M, Kaelin WJ, Jr. 2003. HIF hydroxylation and the mammalian oxygen-sensing pathway. J. Clin. Invest. 111:779-83
80. Aiello LP, Avery RL, Arrigg PG, et al. 1994. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331:1480-87
81. Malecaze F, Clemens S, Simorer-Pinotel V, et al. 1994. Detection of vascular endothelial growth factor mRNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch. Ophthalmol. 112:1476-82
82. Aiello LP, Pierce EA, Foley ED, et al. 1995. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA 92:10457-61
83. Adamis AP, Shima DT, Tolentino MJ, et al. 1996. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch. Ophthalmol. 114:66-71
84. Ozaki H, Seo MS, Ozaki K, et al. 2000. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am. J. Pathol. 156:697-707
85. Congdon N, O'Colmain B, Klaver CC, et al. 2004. Causes and prevalence of visual impairment among adults in the United States. Arch. Ophthalmol. 122:477-85
86. Ferris FL, 3rd, Fine SL, Hyman L. 1984. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch. Ophthalmol. 102:1640-42
87. Barbazetto I, Burdan A, Bressler NM, et al. 2003. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment - TAP and VIP Report No. 2. Arch. Ophthalmol. 121:1253-68
88. 1999. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials - TAP Report 1. Arch. Ophthalmol. 117:1329-45
89. Gragoudas ES, Adamis AP, Cunningham ET, Jr., et al. 2004. Pegaptinib for neovascular age-related macular degeneration. N. Engl. J. Med. 351:2805-16
90. Ferrara N, Damico LA, Shams N, et al. 2006. Development of ranibizumab, an anti-VEGF antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26:859-70
91. Ng EW, Sima DT, Calias P, et al. 2006. Pegaptinib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5:123-32
92. Chen Y, Wiesmann C, Fuh G, et al. 1999. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J. Mol. Biol. 293:865-81
93. Rosenfeld PJ, Brown DM, Heier JS, et al. 2006. Ranibizumab for neovascular age-related macular degeneration: 2-year results of the MARINA study. N. Engl. J. Med. In press
94. Kaiser PK. 2006. Presented at Macula 2006, New York, Jan. 14
95. Tolentino MJ, Brucker AJ, Fosnot J, et al. 2004. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina 24:660
96. Shen J, Samul R, Silva RL, et al. 2006. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther. 13:225-34
97. PKC-DRS Study Group. 2005. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase Cβ Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 54:2188-97
98. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. 2005. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg. Lasers Imag. 36:331-35
99. Avery RL, Pieramici DJ, Rabena MD, et al. 2006. Intravitreal bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363-72
100. Jubb AM, Hurwitz HI, Bai W, et al. 2006. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J. Clin. Oncol. 24:217-27